Sarah Hubbard
Physician Assistant · Richmond, VANPI 1891871836
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,090 of the $34,866 with a category attached, or 60.5%. Gilead accounts for 89.0% of it on its own, with 22 other manufacturers making up the rest. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $156.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$31K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AstraZeneca$335
- Ipsen Biopharmaceuticals, Inc$221
- Eisai Inc.$204
- Genentech USA, Inc.$185
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$21,09060%
- Travel & lodging$7,06620%
- Food & beverage$6,70919%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 92 | $31,015 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 74 | $1,511 |
| AstraZeneca(2 entities) | 5 | $335 |
| Ipsen Biopharmaceuticals, Inc | 3 | $221 |
| Eisai Inc. | 10 | $204 |
| Genentech USA, Inc. | 5 | $185 |
| Fujifilm Healthcare Americas Corporation | 2 | $147 |
| Histosonics, Inc. | 1 | $142 |
| Boston Scientific | 1 | $136 |
| Intercept Pharmaceuticals, Inc. | 5 | $123 |
| Tarsus Pharmaceuticals, Inc. | 1 | $123 |
| Novo Nordisk | 1 | $122 |
| Mallinckrodt Hospital Products Inc. | 1 | $109 |
| AbbVie | 6 | $100 |
| W. L. Gore & Associates, Inc. | 4 | $80 |
| Astellas Pharma US Inc | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $67 |
| Intra-sana Laboratories | 1 | $55 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| GSK | 1 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Echosens North America, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,866 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 97 | $321,889 |
| EpclusaSofosbuvir/Velpatasvir | 12 | $281,621 |
| OcalivaObeticholic Acid | 25 | $230,423 |
| LivdelziSeladelpar Lysine | 14 | $199,951 |
| VemlidyTenofovir Alafenamide | 36 | $55,818 |
| Ursodiol | 177 | $40,339 |
| Mycophenolate Mofetil | 71 | $4,406 |
| Lactulose | 91 | $3,160 |
| Tacrolimus | 40 | $2,784 |
| Tenofovir Disoproxil Fumarate | 53 | $2,053 |
| Spironolactone | 130 | $1,537 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $1,463 |
| ConstuloseLactulose | 22 | $753 |
| Furosemide | 142 | $485 |
| Azathioprine | 18 | $417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Livdelzi, Vemlidy | $31,015 | $537,39062 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,511 | $321,88997 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $123 | $230,42325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Richmond
- Robert HigginsonRichmond$66K
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
- Juliette BeristainVirginia Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.